Boston to host biggest LSPN North America–Spring Conference
LSIPR is gearing up for the 6th annual LSPN North America–Spring Conference, starting tomorrow, May 8, in Boston, Massachusetts.
Held at the Sheraton Boston, this year’s two-day event has the most participants to date, amassing in-house counsel from the world’s leading pharmaceutical and biotechnology companies.
LSIPR will be reporting live from the event, bringing exclusive coverage of the panel sessions.
Eldora Ellison, chairperson of the event and director at Sterne Kessler, said: “I am delighted that this conference brings together over 200 attendees from around the world, spanning the breadth of pharma, biotech, and medtech companies.”
“Our speakers will provide practical guidance and updates on topics such as the Unified Patent Court (UPC), patent strategies in view of clinical trial disclosures, multijurisdictional patent litigation, and mental health and IP,” she added.
Covering everything from patentability to eligibility, prosecution to litigation, the agenda will provide valuable insights into the entire lifecycle of US patent protection.
The speakers include Adam Gastonguay, patent counsel from Regeneron, Jacqueline Bonilla, senior legal advisor at the US Patent and Trademark Office (USPTO) Jocelyn Ram, IP counsel from the Broad Institute of MIT and Harvard, Joshua Buchman, senior patent attorney at Novartis, and Matt Flinders, patent attorney at Roche.
Panel sessions include:
- The UPC-lessons from the first year
- Maximising patent value in China: Navigating post-filing data, patent term extension adjustments and employee service inventions
- Navigating enablement and written description requirement standards in the USPTO
- The Challenge of Protecting Patents and Innovation: Obviousness-type double patenting after In re Cellect.
Attendees will have the opportunity to take part in extended roundtable discussion groups, spending a few hours in small groups, sharing views on a range of relevant topics.
The roundtable discussion topics include AI and machine learning in drug discovery: Patenting AI-generated innovations, IP issues in protecting CRISPR, CAR-T and other immunotherapies, and the best practice in patenting antibodies.
“There’s something here for everyone,” added Ellison.
In addition to the informative sessions, attendees will have networking opportunities throughout the day and into the evening, including coffee breaks and a three-course lunch.
For more information on this or LSPN Fall 2024 in San Francisco, contact:
SPEAKING:
Conference Producer: Hannah Gore
SPONSORSHIP:
Partnerships Director, Events: Kirsty Pocock
REGISTRATION:
Delegate Sales Manager: Adrian Tapping
